BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 16750259)

  • 21. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tamoxifen and endometrial pathology].
    Negoiţă M; Terinte C; Mihailovici MS
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen.
    Cohen I; Altaras MM; Shapira J; Tepper R; Cordoba M; Figer A; Zalel Y; Dror Y; Beyth Y
    Gynecol Obstet Invest; 1997; 43(1):60-3. PubMed ID: 9015703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hysteroscopic assessment of menopausal breast-cancer patients taking tamoxifen; there is a bias from the mode of endometrial sampling in estimating endometrial morbidity?
    Garuti G; Grossi F; Cellani F; Centinaio G; Colonnelli M; Luerti M
    Breast Cancer Res Treat; 2002 Apr; 72(3):245-53. PubMed ID: 12058966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer.
    López DM; Fernández YG; Sánchez AV; Alvarez MI; Reynaldo MI; Delgado RC
    Menopause; 2013 Jan; 20(1):64-71. PubMed ID: 22968254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen.
    Marchesoni D; Driul L; Fabiani G; Di Loreto C; Cataldi P; Mozzanega B
    Int J Gynaecol Obstet; 2001 Dec; 75(3):257-62. PubMed ID: 11728486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Some specifics of tamoxifen's effect on the endometrium in menopausal cancer patients].
    Ashtrafian LA; Antonova IB; Chazova NL; Motskobili TA; Babaeva NA; Al'ditskiĭ IA
    Vopr Onkol; 2005; 51(2):200-5. PubMed ID: 16223001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer.
    Garuti G; Cellani F; Colonnelli M; Garzia D; Gonfiantini C; Luerti M
    J Am Assoc Gynecol Laparosc; 2004 Feb; 11(1):62-7. PubMed ID: 15104834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
    Jeon J; Kim SE; Lee DY; Choi D
    Breast Cancer Res Treat; 2020 Jan; 179(1):125-130. PubMed ID: 31541382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ultrasound endometrium follow-up during tamoxifen treatment: Really not reliable or useful after all?].
    Burkart C; Wight E; Pók J; Kernen B; Traber M; Haller U; Bajka M
    Ultraschall Med; 2001 Jun; 22(3):136-42. PubMed ID: 11484445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen.
    Hann LE; Gretz EM; Bach AM; Francis SM
    AJR Am J Roentgenol; 2001 Aug; 177(2):337-42. PubMed ID: 11461858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
    Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
    J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of influencing factors of endometrial disease of patients with breast cancer after operation].
    Pan NP; Zhou WX; Tang J; Zhou JH; Li JQ
    Zhonghua Fu Chan Ke Za Zhi; 2019 Dec; 54(12):848-853. PubMed ID: 31874475
    [No Abstract]   [Full Text] [Related]  

  • 39. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Zhu Y; Yang J
    J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
    Kavak ZN; Binöz S; Ceyhan N; Pekin S
    Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.